
Opinion|Videos|June 17, 2024
Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer
Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
4
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
5
































